Viking Therapeutics, Inc. CEO Brian Lian's Stock Transactions

The filing reports two significant stock transactions by Brian Lian, the President & CEO of Viking Therapeutics, Inc. On October 27, 2025, Lian acquired 70,084 shares of common stock as part of a performance restricted stock unit award that vested upon the achievement of non-financial performance goals. This transaction increased his total holdings to 2,458,098 shares. The following day, October 28, 2025, Lian sold 38,989 shares at a weighted average price of $35.0079 to satisfy tax withholding obligations related to the vesting of the stock award. This sale reduced his total holdings to 2,419,109 shares. The filing highlights the automatic nature of the sale and provides detailed information on the price range of the sold shares.